Guest Post by David Kliff, Editor, Diabetic Investor

Whether the toy makers realize it or not, the key to getting their toys played with is to make the toy as easy to use as possible. This ease of use does not just mean things like easy insertion of a sensor, like Dexcom has done with the G6 or Abbott has done with the Libre. It goes beyond not having to calibrate either of these sensors. When it comes to increasing the use of insulin, it means making dosing insulin as “stupid” as possible; take all the decisions out of the hands of the patient.

True or False: there is an antidiabetic medication available on the US market with an indication from the US Food and Drug Administration (FDA) to prevent cardiovascular (CV) disease. Follow the link for the answer.

What percentage of your patients with diabetes would benefit from Real-Time CGM? 0 to 25%, 26% to 50%, 51% to 75%, or 76% to 100%? Follow the link and see how you compare to your colleagues.

The addition of mealtime insulin to a patient’s diabetes regimen can definitely increase the risk of hypoglycemia. This can be exacerbated if the patient is not counting carbs or doing before-meal glucose checks. This month in our special edition we look at the value of using an SGLT-2 Inhibitor instead …

Exposure to calorie count increases consumers' support for requiring calorie labels

The age-old question of which came first “the chicken or the egg” takes on new meaning this week in relation to what you can eat and, more importantly, in what order. Dr. Alpana Shukla, Assistant Professor, Weill Cornell Medicine, sat down with Joy Pape, our Medical Editor, at the recent ADA …

Although GLP-1's don't usually cause hypoglycemia except when given with insulin or a sulfonylurea, I have found that when patients who do not have diabetes are started on a GLP-1, some can have symptoms of hypoglycemia and/or more untoward GI side effects if they start when they come in the office fasting.

Alpana Shukla MD, MRCP (UK) graduated from Grant Medical College Mumbai, India and trained in Endocrinology in the UK and Australia. She is Assistant Professor of Research in the Division of Endocrinology, Diabetes & Metabolism at Weill Cornell Medical College, and Director of Clinical Research at the Comprehensive Weight Control Center. Dr Shukla is a research mentor for the MS program at the Institute of Human Nutrition, Columbia University. Her research interests and publications include novel behavioral interventions for management of type 2 diabetes and obesity, pharmacotherapy for obesity, and metabolic surgery.

In the conclusion of this week's Homerun Slides, the clinical performance of the Eversense CGM System.

High density mapping: GWAS do not inevitably lead to identification of a gene or genes in a given locus associated with disease.The most strongly associated SNPs are often only markers for the functional variant responsible for the observed genetic effect and most associated regions harbor several genes. Therefore, additional fine mapping of the loci in even larger sample sets is often necessary. To do this cost-efficiently a Cardio-Metabochip has been developed for metabolic/cardiovascular gene mapping. This custom-design Illumina Infinium genotyping chip contains ∼200,000 polymorphisms selected to cover association signals from a wide range of metabolic disorders (T2DM, lipid disorders, obesity, and cardiovascular disease), was designed to perform both deep replication of major disease signals and fine mapping of established loci. Meta-analysis of previous GWAS with an additional 22,669 T2DM cases and 58,119 controls genotyped using the Cardio-Metabochip has recently added another eight new loci associated with T2DM in the European population